In last trading session, Mural Oncology plc (NASDAQ:MURA) saw 0.54 million shares changing hands with its beta currently measuring 4.65. Company’s recent per share price level of $1.13 trading at -$0.1 or -8.13% at ring of the bell on the day assigns it a market valuation of $19.47M. That closing price of MURA’s stock is at a discount of -338.94% from its 52-week high price of $4.96 and is indicating a premium of 1.77% from its 52-week low price of $1.11. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.88 million shares which gives us an average trading volume of 267.71K if we extend that period to 3-months.
For Mural Oncology plc (MURA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -2.02 in the current quarter.
Mural Oncology plc (NASDAQ:MURA) trade information
Upright in the red during last session for losing -8.13%, in the last five days MURA remained trading in the red while hitting it’s week-highest on Wednesday, 04/02/25 when the stock touched $1.13 price level, adding 17.52% to its value on the day. Mural Oncology plc’s shares saw a change of -64.91% in year-to-date performance and have moved -4.24% in past 5-day. Mural Oncology plc (NASDAQ:MURA) showed a performance of -68.35% in past 30-days. Number of shares sold short was 0.41 million shares which calculate 4.53 days to cover the short interests.
In 2025, company’s earnings growth rate is likely to be around 36.39% while estimates for its earnings growth in next 5 years are of 30.32%.
Mural Oncology plc (NASDAQ:MURA)’s Major holders
Insiders are in possession of 1.62% of company’s total shares while institution are holding 60.66 percent of that, with stock having share float percentage of 61.67%. Investors also watch the number of corporate investors in a company very closely, which is 60.66% institutions for Mural Oncology plc that are currently holding shares of the company. ARMISTICE CAPITAL, LLC is the top institutional holder at MURA for having 1.69 million shares of worth $5.3 million. And as of 2024-06-30, it was holding 9.9735 of the company’s outstanding shares.
The second largest institutional holder is SOLAS CAPITAL MANAGEMENT, LLC, which was holding about 1.27 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4979 of outstanding shares, having a total worth of $3.98 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 482.63 shares of worth $0.55 million or 2.80% of the total outstanding shares. The later fund manager was in possession of 236.78 shares on Dec 31, 2024 , making its stake of worth around $0.27 million in the company or a holder of 1.37% of company’s stock.
